Description

Daraxonrasib RMC-6236 Research Compound

What is Daraxonrasib?

Daraxonrasib, also known as RMC-6236, is an advanced research compound being studied in the field of targeted oncology and RAS-driven cancer research. It belongs to a class of compounds known as RAS inhibitors, with particular interest in cancers linked to abnormal RAS signaling.

RAS proteins play an important role in cell growth, cell division, and survival pathways. When RAS becomes mutated or overactive, it can contribute to uncontrolled cell growth, making it a major area of interest in modern cancer research.

Daraxonrasib is being investigated because of its ability to target active RAS signaling pathways, including multiple RAS variants that are commonly associated with difficult-to-treat cancers.

Important Research Use Notice

Daraxonrasib RMC-6236 is intended for research use only. It is not approved for human consumption, veterinary use, self-medication, or unsupervised therapeutic application.

This information is provided for educational and research reference only. It should not be interpreted as medical advice or as a recommendation for treatment. Any clinical use must occur only within authorised and properly controlled research or clinical trial settings.

How Does Daraxonrasib Work?

Daraxonrasib is designed to target the active form of RAS, often referred to as RAS(ON). In research settings, it works by forming a non-covalent tri-complex with cyclophilin A and active RAS. This interaction helps block RAS from connecting with downstream signaling partners.

By interfering with these signaling interactions, Daraxonrasib may help suppress the MAPK pathway, a key pathway involved in cancer cell growth and survival.

This mechanism makes Daraxonrasib an important compound of interest for studying cancers driven by RAS pathway activity.

Key Research Areas

Daraxonrasib is being explored in several advanced research areas, including:

• RAS-driven cancer research
• KRAS mutation studies
• MAPK pathway research
• Targeted oncology research
• Precision medicine research
• Pancreatic cancer research
• Colorectal cancer research
• Non-small cell lung cancer research
• Drug resistance and combination therapy studies

Because RAS mutations are found in several aggressive cancer types, compounds such as Daraxonrasib are being studied for their potential role in next-generation oncology research.

Daraxonrasib and RAS Mutation Research

RAS mutations are among the most studied genetic alterations in cancer biology. Daraxonrasib is of particular interest because it is being investigated for activity across multiple RAS variants, including certain KRAS mutations.

Research interest includes RAS variants such as:

• KRAS G12D
• KRAS G12V
• KRAS G13D
• Other RAS-driven mutation contexts

This broader RAS targeting profile makes Daraxonrasib different from older approaches that focus on only one specific mutation type.

Potential Research Benefits

Daraxonrasib is being studied for its potential to support research into:

• Inhibition of RAS-driven signaling
• Suppression of MAPK pathway activity
• Reduction of cancer cell proliferation in research models
• Tumor biology and targeted therapy studies
• Resistance mechanisms in oncology research
• Combination therapy strategies

Early research suggests that Daraxonrasib may be useful for investigating tumors that depend heavily on RAS signaling, but further clinical investigation is needed to fully understand its safety, effectiveness, and long-term potential.

Chemical and Product Information

Product name: Daraxonrasib
Alternative name: RMC-6236
CAS number: 2765081-21-6
Product type: Research compound
Research class: RAS inhibitor
Target pathway: RAS / MAPK signaling pathway
Research focus: Targeted oncology and RAS-driven cancer research
Molecular formula: C44H58N8O5S
Molecular weight: 811.06 g/mol

Storage and Handling

Daraxonrasib should be handled only by qualified professionals in a suitable research or laboratory environment.

General storage guidance may include:

• Store in a dry and dark environment
• Protect from direct sunlight
• Keep tightly sealed when not in use
• Follow the storage temperature recommended by the supplier
• Use appropriate laboratory safety procedures when handling
• Refer to the certificate of analysis and safety data sheet before use

Researchers should always follow their institutional safety protocols and local regulations when storing, handling, or disposing of research compounds.

Who is Daraxonrasib Intended For?

Daraxonrasib is intended for use by qualified research professionals, including:

• Laboratory researchers
• Oncology research teams
• Pharmaceutical research professionals
• Academic research institutions
• Clinical research organisations
• Scientists studying RAS-driven cancer pathways

It is not intended for personal use, cosmetic use, self-treatment, or direct patient use outside authorised clinical research.

Safety and Compliance Information

Daraxonrasib remains a research compound and should be used only in compliance with applicable laboratory, ethical, and regulatory standards.

Researchers are responsible for ensuring that use of this compound complies with all local laws, institutional review requirements, import regulations, and safety guidelines.

This product should not be used by individuals who are pregnant, breastfeeding, have a medical condition, or are taking medication unless such use is part of an authorised clinical research protocol supervised by qualified professionals.

Why Choose Peptides Weight Health?

At Peptides Weight Health, we aim to provide clear, responsible, and quality-focused information about advanced research compounds and peptide-related products.

Our platform is built around:

• Clear product information
• Quality-focused research products
• Responsible product descriptions
• Discreet and professional service
• Secure online ordering experience
• Support for informed decision-making
• A commitment to safety and compliance

We help researchers and professional users better understand the products they are reviewing, while maintaining responsible communication around research-only compounds.

Daraxonrasib Product Summary

Product name: Daraxonrasib
Also known as: RMC-6236
CAS number: 2765081-21-6
Product category: Research Compounds
Sub-category: Oncology Research Compounds
Research class: RAS inhibitor
Primary research focus: RAS-driven cancer research
Status: Research use only